Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| It's really combined result of stronger -- of strong '23 results and execution |
| And again, we are pleased to give pretty solid and healthy '24 guidance |
| For the full-year 2023, we delivered industry-leading 14.5% organic revenue growth, which shows remarkable resiliency and consistency under difficult market conditions |
| Moreover, 2023 was our third consecutive year of double-digit organic revenue growth a testament to the strong execution of our Bruker colleagues across the globe and to our differentiated innovation strategy and culture of disciplined entrepreneurialism |
| Importantly, in fiscal 2023, we also delivered a solid 10.3% non-GAAP EPS growth year-over-year, all while investing significantly in R&D, capacity and productivity and in selected strategic bolt-on acquisitions |
| We're pleased with how that's performing |
| As we look at the fiscal year 2024, we entered the year with solid bookings momentum, a strong backlog and a positive outlook for Bruker to emerge as a leader of the post-genomic era and financially to again achieve above-market organic revenue and non-GAAP EPS growth |
| In the fourth quarter of '23, Bruker delivered excellent organic revenue growth of 15.9% and solid pro forma non-GAAP EPS growth |
| So I'm pretty encouraged about where we are |
| Our cash flow position actually for 2023 improved sharply from '22 |
| Still early days, but a nice aftermarket growth, if you like, first of all, something we're always trying to strengthen then, of course with good, very good gross margin and operating margin potential and just good revenue growth potential |
| Our strong organic operating margin expansion is evidence of the success of our Project Accelerate and operational excellence initiatives |
| So we're pleased with that |
| On Slide 5, you can see Bruker's strong performance and excellent execution in 2023 with industry-leading organic revenue growth of 14.5%, solid non-GAAP EPS growth of plus 10.3% and excluding BCA even pro forma non-GAAP EPS growth of plus 14.5% |
| about a year ago, 1.5 years ago and the pending potential Chemspeed acquisitions also have software components and we'll benefit from some of the software assets that we have already in this IDS |
| And the assets that we have acquired and now -- to some extent, are integrating, right? We provide nice portfolio, vendor agnostic, scientific and lab digitization software solutions that we think has good growth potential with excellent margin potential |
| And you can see solid non-GAAP EPS growth of 10.3% despite a $0.10 headwind from BCA in the fourth quarter |
| They have market traction, demonstrated and margin traction demonstrated in some markets |
| So we think we're well positioned |
| And there, we are just very well -- or increasingly very well positioned and really strongly positioned in proteomics, lipidomics, metabolomics, glycomics, you name it |
| Unfortunately, this is not a zero-sum game, but a growing market as far as we can tell with very healthy fundamental dynamics, and we expect to continue to do well and that in 2024 |
| For '23, our CALID group had revenue of $960 million and constant exchange rate growth in the high teens percentage with strong growth in life science mass spectrometry driven by the timsTOF platform and aftermarket business as well as strong growth in applied mass spectrometry and our optics infrared, near-infrared and Raman business |
| So we expect continued steady growth in a growing proteomics market |
| Fiscal year '23, Bruker Nano revenue was $942 million, and in constant exchange rate, Nano grew in the high teens percentage with strong revenue growth across markets, including academic government, industrial, and semiconductor metrology |
| The artificial intelligence megatrend is a strong tailwind for our semiconductor metrology and advanced packaging tools |
| Revenues for our advanced X-ray solutions and Nano surfaces, core tools also showed strong growth |
| Fluorescence microscopy revenue was up on solid growth in academic government research as well as contributions from our Q4 '22 acquisition of the Inscopix neuroscience research tools |
| Finally, 2023 best revenues grew in the mid-teens percentage net of intercompany eliminations, driven by share gains and superconductor demand by our MRI OEM customers as well as by growth in big science, fusion research, and key new extreme ultraviolet EUV technologies for semiconductor lithography tools by large OEM customers, all in support of the strong AI or artificial intelligence demand |
| And the pull forward, therefore is primarily driven by very good organic growth and margin developments and expected very good EPS growth also in -- then in '25, '26 which is primarily an organic development |
| They are a specialist in research Raman microscopy systems so far, primarily are only offered in Japan and Korea, but we think these products will do very well outside of Japan and Korea as well, since they're really performance-leading with exceptional speed, sensitivity, spatial resolution and user-friendly workflows in research Raman microscopy |
| Statement |
|---|
| Finally, fourth quarter 2023 non-GAAP EPS of $0.70 was down 5.4% compared to the fourth quarter of '22, with a $0.10 headwind from BCA |
| Our fourth quarter '23 non-GAAP operating margin was 18.1%, which was down 290 bps, primarily due to the dilutive PhenomeX acquisition in Q4 '23, as well as headwinds from other M&A and currency |
| On a non-GAAP basis, Q4 2023 diluted EPS was $0.70, down 5.4% from $0.74 in the fourth quarter of '22, primarily due to the $0.10 dilutive effect of our Phenomics acquisition in the fourth quarter as well as a challenging tax rate comparison year-over-year |
| We also expect softer operating margin performance in the first quarter of 2024 driven by BCA dilution and other acquisition and foreign exchange headwinds |
| On a non-GAAP basis, Q4 '23 diluted EPS was $0.70, down 5.4% from $0.74 in the fourth quarter of '22, primarily due to the PhenomeX acquisition in Q4 '23 |
| Fourth quarter 2023 non-GAAP operating margin of 18.1% was 290 basis points lower than the 21% margin performance we posted in the fourth quarter of '22 as foreign exchange and acquisition headwinds primarily from BCA more than offset strong organic operating margin expansion of 270 basis points |
| Gerald Herman And I would just say China had, I would say a bit of a recovery in the fourth quarter where we saw some challenges in the third quarter relative to that particular market |
| So recall that we acquired it basically the beginning of Q4 of '23 and there was quite a drag on margins |
| Non-GAAP gross margin of 51.8% decreased 80 basis points from 52.6% in the fourth quarter '22 impacted by foreign exchange and acquisition headwinds, partially offset by organic gross margin improvements of about 40 basis points year-over-year |
| For non-GAAP operating margins, all in, we expect about an 80 basis point decline from the prior year due to a combined 130 basis point headwind from foreign exchange and acquisitions |
| Non-GAAP gross margin performance was down 80 basis points year-over-year in the fourth quarter of '23 negatively impacted by foreign exchange and M&A headwinds, partially offset by organic gross margin expansion of about 40 basis points year-over-year |
| We expect first quarter organic revenue to be sequentially below the fourth quarter of '23 and only modestly above the first quarter of 2023, which was an exceptionally strong first quarter |
| I'm starting to get some questions from investors about, obviously, what's going on with China and your sales into the semiconductor market and people are starting to worry about competition and just pushbacks |
| It's an unprecedented level of geopolitical risk and everybody is facing that the industry is facing |
| and China noise |
| Can you just talk about that on the earnings side, particularly, I think it implies almost 30% growth in '25 on the earnings side? Is that -- some of these deals slipping accretive? Obviously, the headwinds on the margins last year and this year from the deal has been notable |
| Then indeed as some of these headwinds either go away or abate |
| Frank Laukien Well, geopolitical risks for us is code for a Ukrainian-Russian war and Israel-Hamas war and the potential of some more like action around Taiwan happening at some point or these war spreading |
| Accordingly, in fiscal year '24, we expect the quarterly BCA non-GAAP EPS dilution to be significantly reduced to just $0.02 to $0.03 per quarter with a significant further drop in dilution expected in fiscal year '25 and BCA profitability anticipated in fiscal year '26 |
| So they are with two war spending and they increased risk of a conflict over Taiwan and possible at some point in the next decade |
Please consider a small donation if you think this website provides you with relevant information